华法林给药算法的系统综述
该系统综述检索了MEDLINE截至2020年5月20日的文献,纳入266篇文章,描述了433个华法林给药算法的开发、481次外部验证和52项临床效用评估。大多数算法用于剂量初始化(86%),主要适用于亚洲人(49%)或白人(43%)。仅26%和7%的算法分别进行了外部验证和临床效用评估,且不到2%的算法开发或外部验证被评为低偏倚风险。
要点
- 大多数华法林给药算法针对亚洲人和白人开发,可能不适用于服务不足人群。
- 仅26%的算法进行了外部验证,7%评估了临床效用,低偏倚风险者不足2%。
- 年龄、合并用药和体重是最常见的非遗传协变量,CYP2C9、VKORC1和CYP4F2是最常见的遗传协变量。
核心结论
- 大多数华法林给药算法在亚洲人和白人中开发,可能不适用于服务不足人群。
- 很少算法经过外部验证、临床效用评估或具有低偏倚风险,使其临床使用不可靠。
- 算法开发和评估应遵循当前方法学建议,并优先考虑代表性不足的人群。
研究设计与样本
- 系统综述,检索MEDLINE截至2020年5月20日,纳入描述多变量华法林给药算法开发、外部验证或临床效用的研究。
- 由两名研究者进行数据提取和质量评估。
主要发现
- 大多数开发的算法用于剂量初始化(86%),通过多元线性回归开发(65%),主要适用于亚洲人(49%)或白人(43%)。
- 最常见的协变量:年龄(401个算法)、合并用药(270个算法)、体重(229个算法);CYP2C9(329个算法)、VKORC1(319个算法)、CYP4F2(92个算法)是最常见的遗传协变量。
- 仅26%的算法进行了外部验证,7%评估了临床效用;不到2%的算法开发和外部验证被评为低偏倚风险。
临床怎么用
- 临床使用华法林给药算法时应谨慎,因大多数算法缺乏外部验证、临床效用评估和低偏倚风险证据。
- 应考虑算法开发人群与患者的匹配性,避免将主要针对亚洲人或白人开发的算法直接用于其他人群。
局限性
- 仅检索MEDLINE,可能遗漏其他数据库的研究。
- 不到2%的算法开发和外部验证具有低偏倚风险,整体方法学质量较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Numerous algorithms have been developed to guide warfarin dosing and improve clinical outcomes. We reviewed the algorithms available for various populations and the covariates, performances and risk of bias of these algorithms. METHODS: We systematically searched MEDLINE up to 20 May 2020 and selected studies describing the development, external validation or clinical utility of a multivariable warfarin dosing algorithm. Two investigators conducted data extraction and quality assessment. RESULTS: Of 10 035 screened records, 266 articles were included in the review, describing the development of 433 dosing algorithms, 481 external validations and 52 clinical utility assessments. Most developed algorithms were for dose initiation (86%), developed by multiple linear regression (65%) and mostly applicable to Asians (49%) or Whites (43%). The most common demographic/clinical/environmental covariates were age (included in 401 algorithms), concomitant medications (270 algorithms) and weight (229 algorithms) while CYP2C9 (329 algorithms), VKORC1 (319 algorithms) and CYP4F2 (92 algorithms) variants were the most common genetic covariates. Only 26% and 7% algorithms were externally validated and evaluated for clinical utility, respectively, with <2% of algorithm developments and external validations being rated as having a low risk of bias. CONCLUSION: Most warfarin dosing algorithms have been developed in Asians and Whites and may not be applicable to under-served populations. Few algorithms have been externally validated, assessed for clinical utility, and/or have a low risk of bias which makes them unreliable for clinical use. Algorithm development and assessment should follow current methodological recommendations to improve reliability and applicability, and under-represented populations should be prioritized.
引用
- Asiimwe IG, Zhang EJ, Osanlou R, et al. Warfarin dosing algorithms: A systematic review. Br J Clin Pharmacol. 2020. PMID: 33080066. doi:10.1111/bcp.14608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。